



DR CRAIG ROBERTS (Orcid ID : 0000-0002-0653-835X)

Article type : Commissioned Review or Article

How does Toxoplasmosis affect the maternal-fetal immune interface and pregnancy?

Running title: Toxoplasma immune response and pregnancy

Margarida Borges^{1*}, Tânia Magalhães Silva², Carina Brito¹, Natércia Teixeira¹ and Craig W. Roberts^{3*}

¹ UCIBIO/REQUIMTE, Department of Biological Sciences, Faculty of Pharmacy University of Porto, Porto, Portugal.

² Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.

³ Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.

Correspondence to: Margarida Borges, University of Porto. Email: mborges@ff.up.pt; Craig W. Roberts, University of Strathclyde. Email: c.w.roberts@strath.ac.uk

Disclosures: no conflicts of interest.

Keywords: Zoonosis, Congenital Toxoplasmosis, Immunopathogenesis, Maternal-fetal Interface, Activated-Macrophage, Pregnancy.

Disclosures

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/pim.12606

This article is protected by copyright. All rights reserved.

Summary

Toxoplasma gondii is a zoonotic parasite which, depending on the geographical location, can infect between 10 to 90% of humans. Infection during pregnancy may result in congenital toxoplasmosis. The effects on the fetus vary depending on the stage of gestation in which primary maternal infection arises. A large body of research has focused on understanding immune response to toxoplasmosis, although few studies have addressed how it is affected by pregnancy or the pathological consequences of infection at the maternal-fetal interface. There is a lack of knowledge about how maternal immune cells, specifically macrophages are modulated during infection and the resulting consequences for parasite control and pathology. Herein, we discuss the potential of *T. gondii* infection to affect the maternal-fetal interface and the potential of pregnancy to disrupt maternal immunity to *T. gondii* infection.

1. Introduction

Toxoplasma gondii is a protozoan parasite with a global distribution. It is an important pathogen of humans and their livestock. In humans, it can cause abortion or a spectrum of clinical diseases dependent on the parasite isolate, the host immune status and whether infection is acquired post-natally or in utero^{1,2}. *T. gondii* infection causes substantial losses due to abortion in livestock (including sheep, goats and pigs) and the ability of livestock to act as reservoir of disease is a public health risk³. Limited genetic variability has been recognised in *T. gondii* strains isolated from Europe and North America for some time. The vast majority of *T. gondii* isolates characterised to date can be classified as Type I, II and III⁴. Each of these canonical *T. gondii* lineages have different patterns of virulence as empirically determined in mice and supported by restriction length polymorphisms, isoenzyme analysis, large-scale genome sequencing and transcriptomics. However, more recent analyses of *T. gondii* isolates from diverse geographical regions, most notably South America has revealed a greater genetic diversity with at least 15 haplogroups that fall into 6 major clades^{2,4-7}. The rapidly-replicating tachyzoite life cycle stage predominates for around 10-14 days post infection before differentiating into bradyzoites, which replicate more slowly and form cysts in tissues throughout the body⁸. Tissue cysts are long-lived and are generally not considered responsible for significant disease, although associations with seropositivity and some neuropsychiatric diseases have now been recognised⁹. Infection of immune-competent adults with these canonical strains of *T. gondii* has been generally considered self-resolving. This is largely due to a robust systemic immune response to *T. gondii* that controls, but does not eliminate infection¹⁰. However, tissue cysts are assumed to rupture from time to time and in people with immunodeficiencies disease reactivation occurs, causing neurological

and sometimes ocular or systemic disease⁸. *T. gondii* can also cause congenital disease and abortion, almost exclusively in women infected for the first time during pregnancy¹¹. Congenitally infected individuals are also at risk of repeated disease reactivation, mostly evident through ocular and neurological disease, though the reason for this remains to be determined¹². It is now recognised that certain lineages and recombinant strains of *T. gondii* that are common in South America are responsible for severe disease in humans even when acquired as immune-competent^{5,13}.

2. Immune response during *T. gondii* infection

The major findings concerning systemic *T. gondii* immune response have come from experimental murine models, and much of this has been corroborated through clinical studies and *in vitro* studies^{8,14}. Challenges exist in extrapolating the data between studies as differences including the mouse strain, parasite strain and life-cycle stage used to infect, dose of inoculum and route of infection often varies¹⁵. It is not usually ethically possible to test if the murine studies can be translated into humans as this would involve deliberately infecting humans. Nonetheless a consensus of the sequence of immunological events after infection emerges^{1,14}.

Following oral infection, enterocytes are the first line of defense against *T. gondii*, since this parasite is acquired mainly via oral ingestion in mouse, human and other intermediate hosts. Parasites disseminate within the lymphatic and circulatory systems and spread throughout the body. There is evidence that by invading dendritic cells (DCs) and macrophages, previously recruited by the chemokines secreted by infected enterocytes, *T. gondii* is able to cross endothelial barriers, thus allowing entry into sites such as the brain^{8,15}. Neutrophils, DCs, macrophages and natural killer (NK) cells, have been shown to play an important role in the innate immune response to *T. gondii* by controlling parasite multiplication¹⁰. During acute *T. gondii* infection chemokines, belonging to the CC and CXC chemokine superfamilies and their receptors have an important role in the recruitment of NK, DCs, monocytes, neutrophils and in the induction of T helper (Th)1 and CD8+ cytotoxic T cells, as reviewed elsewhere¹⁶. The process of neutrophil recruitment and control of parasite numbers during the initial stages of *T. gondii* infection has been shown to be dependent on interleukin (IL)-17 signaling¹⁷.

T. gondii has a unique cyclophilin 18 with the ability to bind C-C chemokine receptor type 5 (CCR5) and a number of ligands for toll-like receptors (TLRs) including, glycosylphosphatidylinositol-anchored proteins (GIPLs), heat shock protein 70 (HSP70) and profilin, which interact with TLR-2, 4 and 11^{10,18}. This results in induction of many cytokines including IL-12 produced by parasite-infected DCs, macrophages and neutrophils. Interferon (IFN)- γ acts in a synergic way with tumor necrosis factor (TNF)- α , inducing nitric oxide (NO) production by macrophages. NO can inhibit essential parasite mitochondrial and nuclear enzymes, thereby killing tachyzoites or inducing their conversion to the bradyzoite stage¹⁹. IFN- γ also controls: (1) generation of reactive oxygen intermediates with toxoplasmacidal activity in human infected macrophages; (2) iron deprivation within *T. gondii* infected enterocytes, leading to inhibition of parasite replication; (3) tryptophan starvation through indoleamine-2,3-dioxygenase pathway, inhibiting *T. gondii* growth, and (4) activation of the p47 GTPases that bind to subcellular membranes, such as endoplasmic reticulum and Golgi bodies, thereby mediating disruption of the parasitophorous vacuole by exposing the parasite to the cytosol²⁰. However, an excessive Th1 response leads to tissue damage, which may lead to the development of pathology. Notably, both IL-4 deficient and IL-10 deficient mice have reduced survival following infection with *T. gondii* relative to wild-type mice as a likely consequence of reduced Treg and Th2 cell^{15,21,22}. Thus, the ability of the host to balance this response by maximizing pathogen clearance and minimizing immunopathology¹⁹ (Figure 1).

3. Congenital Toxoplasmosis

Congenital toxoplasmosis constitutes a major problem for human health, leading to severe implications for those affected from fetus to adulthood^{1,8}. However, it is known that the relative risk to the fetus depends on various factors, such as the mother's immunological status and genotype, parasite genotype and virulence as well as the gestational period when infection is acquired^{1,4,8}. Other disease determinants include the infectious dose, whether infection is initiated with oocysts or tissue cysts or the occurrence of co-infections^{1,4}.

Primary *T. gondii* infection in the first trimester is associated with a high risk of several adverse pregnancy outcomes including abortion, stillbirth and premature birth, but with a low risk of congenital transmission¹¹. If pregnancy results in a viable child, *T. gondii* infection may cause a wide range of clinical manifestations, such as neonatal malformations that are severe enough to ultimately result in blindness, chorioretinitis, mental retardation, heart and

brain defects, permanent neurological damage and death¹¹. If transmission occurs at later stages of pregnancy, abortion is unlikely, but the risk of congenital infection is increased (Figure 2)²³. Under these circumstances, infected newborns will often be asymptomatic at birth, but essentially will all develop chorioretinitis later in life^{1,11,24}. If infection occurs prior to pregnancy, the risk to the unborn child is extremely low, even if the mother is re-exposed to another infection. However, there is a growing body of literature which demonstrates, in a small number of cases, that maternal disease reactivation can occur during pregnancy and sometimes result in adverse effects on the developing fetus^{1,11,25,26,27}. In addition, other cases have been reported in which pregnant women with immune suppression due, for example, to HIV infection, have resulted in congenital toxoplasmosis^{28,29}. Furthermore, several studies monitoring females with previously acquired *T. gondii* infection through pregnancy found maternal disease reactivation at the ocular site^{27,30}. The cysts stages are presumed to be the source of disease reactivation in all of the above scenarios. Altogether, these data suggest that in the vast majority of cases, a previous maternal infection protects against congenital transmission, even when exposed to a heterologous challenge. However, hormonal-induced alteration of systemic immunity occurs in some pregnancies and can result in disease activation and, occasionally, in vertical transmission (Figure 2)^{1,25,26,31}

4. Effect of *T. gondii* infection on implantation

Healthy pregnancy is highly dependent on appropriate immune responses from coitus to postpartum^{32,33}. Seminal plasma released during coitus contains a variety of immunologically active components including transforming growth factor (TGF)- β , CXCL8, IFN- γ and prostaglandin E^{34,35}. These mediators are responsible for changes in local gene expression, recruitment of monocytes, DCs, NK cells, T cells and expansion of Treg cells and, thus, sets the immunological context for the first encounter of the maternal immune system with paternal antigens^{33,35,36}. As the blastocyst undergoes implantation, macrophages are required to clear apoptotic maternal uterine cells³⁷⁻³⁹. There is now evidence of progressive maternal immune regulation at the maternal-fetal interface comprising the fetus-derived placenta and the decidua^{33,40}. The development of a decidua is dependent on progesterone and is crucial for implantation^{41,42}. The blastocyst breaches the uterine epithelium, an event that is accompanied by inflammation and infiltration of decidual leukocytes, including NK cells, macrophages, dendritic cells and T cells³³. The success of implantation is dependent on the expression of a number of cytokines and chemokines including leukemia inhibitory factor

(LIF), IL-6, IL-15, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-33, CXCL8, CXCL1, MIP-1 α and RANTES and activation of signalling pathways like JAK-STAT, MAPK, Notch, Smad and PI3K^{33,43,44}. Macrophages, decidual NK cells (dNK), decidual dendritic cells (dDC) and other leukocytes are present in the endometrium at this stage and have been demonstrated to play important roles during implantation and, subsequently, promote tolerance to the fetus^{33,36,38,45}. Treg cells expand in peripheral blood and lymphoid organs in the preimplantation period, migrating and, subsequently, accumulating in the decidual tissue⁴⁶. Besides their importance in ovarian homeostasis and ovulation, these cells have a central role in implantation, preventing maternal anti-fetal responses, and are thus determinant in the maintenance of pregnancy^{33,46}.

The potential for *T. gondii* to disrupt these early events in pregnancy has scarcely been studied. Nevertheless, in murine models, chronic *T. gondii* infection has been shown to increase reproductive failure⁴⁷. These alterations have been attributed to tissue cysts of *T. gondii* in various organs, especially in the brain, potentially causing damage in the hypothalamic–pituitary–gonadal axis and leading to alteration in the female estrus cycle⁴⁷. However, in other infection models, such as for *Trypanosoma cruzi*, inhibition of implantation and cell division has also been described⁴⁷. Nevertheless, *T. gondii* acute infection induces transient changes in systemic expression of many immune mediators, which in theory have the potential to antagonise normal immune changes during pregnancy (Figure 1)^{8,10,17,48-50}.

5. Effect of *T. gondii* infection on the developing placenta, decidua and fetus

As pregnancy progresses there are a number of alterations in the maternal immune system, which facilitate fetoplacental development and prevent fetal rejection³². Successful healthy pregnancy is highly dependent on specific regulation and balance of maternal immune responses within the decidua and placenta. This immune regulation enables growth and provides protection of the semi-allogeneic fetus, expressing paternal major histocompatibility antigens from maternal immune rejection^{51,52}. Dysfunction of this immune regulation by extrinsic factors, as in the case of infection, compromises pregnancy maintenance leading to adverse gestational outcomes⁵³.

T. gondii infection can have profound effects on the systemic maternal cellular immune responses and affects normal immune mechanisms at the maternal-fetal interface and can thus influence pregnancy outcome². *T. gondii* strains with different virulence are known to infect decidual immune cell populations and the placenta, a prime anatomical location to alter immune responses at the maternal-fetal interface^{48,54,55}. On the other hand, the immunomodulation during pregnancy may contribute to the development of an environment (dominated by Th2 and Treg cells) that facilitates the escape of *T. gondii* from the immune response, leading to increased maternal pathology or an increased likelihood of congenital transmission⁵⁶.

6. The placenta and *T. gondii* infection

Trophoblasts are epithelial-type cells that constitute the fetal placenta. Cytotrophoblasts act as stem cells for other trophoblast cell types: the syncytiotrophoblast and extravillous trophoblasts. The syncytiotrophoblast forms a multinucleated cell layer that is directly in contact with maternal blood, allowing an intimate interaction between mother and fetus. Extravillous trophoblasts have the ability to invade maternal tissues. These cells essentially function to protect the fetus from harmful substances, while facilitating the passage of nutrients and factors important for fetal development. The immune response within the placenta provides protection from infection and contributes to maternal tissue remodeling, which is fundamental for fetus development^{1,57}.

Human and experimental animal models have shown that trophoblasts are a component of the innate immune system, since they recognize pathogens, produce chemokines and cytokines, which influence the differentiation and migration of macrophages, NK, Treg and DCs at the decidua⁵⁸⁻⁶⁰. Trophoblasts are responsible for the production of a variety of anti-inflammatory mediators, including TGF- β , IL-10 and Fas ligand⁶¹. However, in some situations, trophoblasts may also initiate signals that promote fetal rejection^{62,63}. For example, studies have demonstrated that activation of TLR3 in the trophoblast, by Poly[I:C], a synthetic analog of viral dsRNA induces preterm delivery in mice. *In vitro* studies demonstrate that Poly[I:C] stimulation of both mouse primary trophoblast or human trophoblast induces a range of cytokines and chemokines (including MCP-1, RANTES, IL-6 and IL-12), supporting the idea that these cells function as an immune regulators and influence the differentiation and migration of immune cells⁶². Although *T. gondii* does not have TLR3 ligands, it does have ligands that can activate TLR2,4 and 11 and these could

have similar effects⁸. Indeed, infection may alter crosstalk, inducing TLR-mediated trophoblast inflammatory or apoptotic responses, influencing the recruited and resident maternal immune cells. In extreme cases, as during *T. gondii* infection, these cells shift from a protective to an aggressive phenotype promoting fetal rejection^{55,60}. Notably in this respect, administration of the TLR4 ligand, lipopolysaccharide (LPS) to pregnant mice induces abortion through the induction of TNF- α and nitric oxide synthase⁶⁴.

Trophoblasts are also inextricably linked to parasite transmission to the fetus, since they are strategically located between maternal and fetal blood circulation systems and are efficiently infected with *T. gondii*⁵⁴. *In vitro* studies using Bewo cells, a human trophoblast cell line, have shown that trophoblast susceptibility to *T. gondii* increases in response to high concentrations of macrophage inhibitory factor (MIF)⁶⁵. In contrast, treatment of Bewo cells with IL-10 or TGF- β promoted *T. gondii* proliferation. In contrast to parallel experiments performed in HELA cells, the addition of IFN- γ to Bewo cells did not curtail *T. gondii* proliferation unless IL-10 or TGF- β were neutralised with specific antibodies⁶⁶. Thus, IFN- γ , was not able to control *T. gondii* proliferation in Bewo cells, contrary to expected, suggesting that this cytokine has different activities at the maternal-fetal interface, depending on other host factors⁶⁶.

Recently, *ex-vivo* experiments, using primary human trophoblasts isolated from placentas of both the second and third trimesters, have shown that syncytiotrophoblast cells are able to restrict *T. gondii* attachment and intracellular parasite replication in an IFN- γ -independent manner⁶⁷. The T regulatory chemoattractant CCL22 expression has been associated with miscarriage⁶⁸, and levels of this ligand were increased in primary human placental cells isolated from full-term placentas in response to *T. gondii* infection⁶⁷. It has also been shown, that earlier in human pregnancy, using mid-gestation chorionic villous explants, trophoblasts was also able to restrict *T. gondii* attachment and increase CCL22 production⁶⁷. Increased trophoblast apoptosis and necrosis occurring after *T. gondii* infection is dependent on inflammatory cytokines, such as IFN γ , which can be a factor in determining pregnancy outcomes in women infected by this parasite⁶⁹. In contrast, IL-10 is able to reduce *T. gondii*-infected trophoblast apoptosis levels⁶⁹. If trophoblast invasion is excessive, which occurs during a *T. gondii* infection, IFN- γ has a dual function, thereby limiting parasite replication and promoting its removal^{40,66}. Adhesion of infected monocytes to trophoblasts could also

promote placental and fetal infection. However, trophoblasts are able to modulate monocyte activity controlling *T. gondii* infection, thus promoting pregnancy maintenance⁷⁰. Overall, the interaction between trophoblast cells and maternal-fetal immune cells, specifically macrophages are likely to determine *T. gondii* survival and putative vertical transmission^{65,66,70,71}.

7. The decidua and *T. gondii* infection

The decidua results from proliferation and differentiation of stromal endometrial cells into decidual stromal cells (DSC) by a process called decidualization. These cells are important for embryo implantation, placentation and modulation of local immune cell functions that are essential for maternal/fetal tolerance and protection against infections. DSC are activated by TLR signalling, produce growth factors, such as G-CSF, cytokines including IL-6 and TNF α , as well as chemokines, like IL-8, CXCL1, and possess the chemokine receptors CXCR4. These chemokines induce the recruitment of T cells, monocytes and peripheral NK, modulating the activation profile at the decidua^{72,73}. Depending on the decidua environment, DSC can contribute to a successful pregnancy or miscarriage^{74,75}. *T. gondii* tropism is not clearly understood, although the decidua/trophoblasts interface is highly vulnerable to infection after parasite dissemination through maternal leukocytes⁵⁴. As yet, there is no description regarding the interplay between DSC and *T. gondii* infection.

8. Decidual immune cells and *T. gondii* infection

The decidua is a highly dynamic immunological tissue composed of different maternal immune cell types, and is also modulated by placental-derived factors^{51,76}. Recently, murine studies have suggested an important role for CCR5 and RANTES in abortion caused by *T. gondii* infection⁷⁷. In fact, it is suggested that embryo loss results from alteration of decidual and trophoblastic function, induced by recruitment of macrophages, DCs and T cells in response to increased expression levels of CCR5 and RANTES, in implantation units from *T. gondii* infected mice⁷⁷. Quantitative proteomic analysis of *T. gondii*-infected human decidual immune cells has revealed differential expression of protein levels involved in immune tolerance, fetal intrauterine growth and trophoblast invasion, essential biological processes during pregnancy. For instance, decreased levels of IL-1 β and increased levels of Granzyme A and CCAAT/enhancer-binding protein β (C/EBP β) expression were found in *T. gondii*-infected decidual immune cells compared with uninfected ones⁷⁸. Decreased IL-1 β levels

Accepted Article

during *T. gondii* infection would affect the immune-balance at the maternal-fetal interface and restrict decidualization, placenta development and development of the fetus⁷⁸. Increased granzyme A levels is indicative of increased NK cells and cytotoxic T cells and again could affect decidualization and fetus development⁷⁸. C/EBP β is involved in ERK1/2 signalling during decidualization in human and mice, and in macrophage activation^{79,80}. These observations suggest that, by interfering with the related-pathways to decidual immune responses, *T. gondii* infection can negatively affect pregnancy outcome⁷⁸.

8.1. Decidual NK cells and *T. gondii* infection

The NK cells present at the uterine mucosa and decidua, referred to as dNK cells, constitute the main leukocyte cell population during implantation and early pregnancy. These cells account for 70% of all decidual leukocytes and are functionally and phenotypically different from blood-circulating NK cells⁸¹. Specifically, the majority of dNK cells are highly granulated and characterized as CD56^{bright}/CD16⁻ non-cytotoxic NK cells^{38,57,81}. These cells interact with the invading trophoblast cells, helping them to migrate and invade, thus contributing to the remodeling of decidual spiral arteries into high-conductance blood vessels. This allows sufficient blood flow at the maternal-fetal interface, which is crucial for a healthy gestation^{38,57,82}. In addition, these cells express angiogenic factors, like vascular endothelial growth factor and angiopoietin-2, contributing to the development of placental vascular bed. dNK cells also secrete a variety of cytokines, such as TNF- α , TNF- β , IL-10, IL-13 and GM-CSF³⁸. These immune cells are the main source of IFN- γ , which are essential for implantation and early placental progression⁴⁸. In recent years, several studies have demonstrated the ability of *T. gondii* to modify the immune profile of decidual cells and to invade and multiply within uterine dNK cells⁴⁰. *T. gondii* infection not only increases IFN- γ secretion by dNK cells, but is also associated with higher levels of trophoblast apoptosis, via the caspase-3 and caspase-8 mediated pathways⁴⁰. Additionally, *T. gondii* infection results in the increase of the expression of the human dNK cell-activating receptor (NKG2D), which may trigger a higher cytotoxic activity of dNK towards trophoblast cells. It is believed that these modifications contribute to abnormal pregnancy outcomes⁸³.

8.2. Decidual macrophages during *T. gondii* infection

Decidual Macrophages (dM ϕ) constitute 20% of the decidual leukocyte population and represent the second most abundant immune cell-type population in decidua^{37,76}. dM ϕ are recruited to the maternal-fetal interface by stromal and trophoblast cells, where they have specialized functions, such as decidual homeostasis, placental development and tolerance to the semi-allogeneic trophoblast. They also form a major line of defense against invading pathogens in the decidua and thus protect the fetus from infection^{37,84,85}. *In vitro* studies have shown that dM ϕ differentiation and polarization are regulated by factors produced by trophoblasts such as IL-10, suppressing IFN γ -induced Stat1 activation⁸⁶. During early gestation, dM ϕ are also major producers of IL-10 and are able to suppress and regulate the decidua immune response^{37,38}. dM ϕ can decrease the cytolytic activity of dNK cells against invading trophoblasts. These leukocytes also play a role in the induction and expansion of Treg cells, contributing to the maintenance and support of uterine tissue homeostasis and remodelling^{37,38,87}.

dM ϕ are able to recognize, phagocytose and eliminate pathogens. In addition, they also remove apoptotic cells and cellular debris and, therefore, promote normal fetal development and acceptance, preventing tissue damage and fetal rejection^{37,38,87,88}. *T. gondii* infection of human trophoblasts modulates trophoblast-macrophage crosstalk, in order to favor its establishment in the host cell⁷¹. The polarization of dM ϕ is modulated by *T. gondii* infection, but it is still unclear at present how this occurs during human pregnancy⁸⁵. Human and animal studies support the occurrence of both classical and alternative activation in macrophages responding to *T. gondii*⁸⁹. Macrophages have a variety of activation states, being able to adapt their functions to cytokine environmental changes, described as innate TLR ligation, classical/M1 or alternative/M2 activation states^{90,91}. Innate macrophages are activated after a microbial stimulus, through LPS stimulation or other TLR ligands, producing TNF- α , IL-6, IL-12 and NO^{92,93}. M1 macrophages are antigen-presenting cells, activated usually through a combination of LPS and IFN- γ , producing IL-12, IL-23 and reactive oxygen species. M2 macrophages can be induced by IL-4, IL-10, IL-13, IL-33, TGF- β and granulocyte-colony stimulating factor (G-CSF)^{87,92} and are important regulators of the wound-healing response, tissue homeostasis and adiposity⁹³.

M1 and M2 macrophages are often associated with polarised Th1 and Th2 responses, respectively. However, M1 and M2 functions can occur either in the presence or absence of T cells⁹⁴. Additionally, during an inflammatory response, M1 and M2 activation profiles are present, suggesting a switch between M1 and M2, thereby highlighting the dual role of macrophages in initiating and, subsequently, resolving inflammation. Whether this switch occurs by local conversion of M1 macrophages to anti-inflammatory M2 cells, or by sequential recruitment from distinct precursor cell populations from the blood is currently under debate⁹⁵. Several studies have shown that M2 activation profile includes several stages^{89,96,97}. Thus, while classical macrophage activation can control *T. gondii* replication through induction of iNOS, alternative activation can control parasite replication through induction of arginase and depletion of arginine, since this parasite is auxotrophic for arginine^{89,98}. M1 macrophages induced by a Th1 response in murine models exhibit cytotoxic and antimicrobial activities against *T. gondii* infection. This same response is also associated with immunopathology and adverse pregnancy outcomes^{89,99}. In humans, during implantation, decidual macrophages consist of a M1/M2 heterogeneous activation profile population. This mixed decidual macrophage profile continues to predominate during the first trimester and at the beginning of the second trimester of pregnancy, coincident with the vasculature remodelling at the uterus. After placental growth, in the final stages of the second trimester, decidual macrophages exhibit predominantly an M2 polarized profile, promoting fetus maintenance and growth^{85,87,92}.

Several studies have focused on macrophage activation profiles in normal and complicated pregnancy. Some of these have associated an imbalance of the macrophage polarization with *T. gondii* intrauterine infection, but failed to determine the context of macrophage polarity and the mechanisms promoting their dysregulation at the maternal-fetal interface⁸⁷. Recently, it has been reported that human dM ϕ upon *T. gondii* infection showed upregulated M1 markers and downregulated M2 macrophage markers concomitantly with a downregulation of human leukocyte immunoglobulin-like receptor subfamily B member 4, an important factor in immune tolerance and immune regulation during normal pregnancy¹⁰⁰. These alterations provide a possible explanation for the disruption of pregnancy^{39,100}. Other infection models, such as malaria during pregnancy indicates that macrophage accumulation in the placenta is a key determinant in the immune pathology associated with this parasite^{101,102}.

8.3. Decidual DCs during *T. gondii* infection

DCs are antigen-presenting cells priming T cell responses, but dDCs fail to initiate immunogenic T cell responses to placental antigens, thus contributing to maternal-fetal tolerance^{38,103}. Despite the fewer number of human DCs at the decidua, they play determinant roles in normal and pathological pregnancies^{104,105}. In addition, DCs are important for materno-fetal tolerance and are also involved in angiogenic responses at the maternal-fetal interface¹⁰⁵. In normal human decidua, both immature myeloid – identifiable by their expression of DC-SIGN (CD209) – and mature myeloid DCs coexist¹⁰⁵. In early human pregnancy the presence of DC-SIGN+ cells and dNK clusters indicate that the interconnection between these cell subsets is essential in pregnancy maintenance¹⁰⁶. In fact, dNK cells induce apoptosis in DC-SIGN+ cells, constituting a mechanism of maternal-fetal tolerance¹⁰⁶. Other models of infection, namely with *Coxiella burnetii* and *Brucella abortus*, revealed that myeloid dDCs are unable to mature in response to bacterial ligands, such as peptidoglycan or LPS, or to produce inflammatory cytokines. This would prevent development of effective immunity and favour pathogen multiplication¹⁰⁷. However, contrary to these observations during bacterial infections, *in vitro* studies have shown that *T. gondii*-infected human dDCs produced IL-12 which increased the cytotoxicity of dNK cells as determined by increased expression of NKG2D and production of IFN- γ . The presence of increased IL-12 and IFN- γ levels would favor Th1 cells and suppress Th2 cells and thus contribute to disruption of pregnancy⁴⁸.

8.4. Decidual T cells and *T. gondii* infection

The relative balance of lymphoid cells, such as Th1, Th2 and Treg cells, present at the decidua coordinate macrophage polarization and are vital for successful pregnancy¹⁰⁸. In the past it was accepted that maternal-fetal immunological balance could be disturbed by *T. gondii* infection by disrupting a pregnancy-induced bias from Th2-type environment (associated with IL-4 and IL-10) toward Th1-type environment (associated with IFN- γ , TNF- α and IL-12 production), which has been demonstrated to be abortogenic. The discovery of new cytokines at the fetal/maternal interface which did not fit the Th1/Th2 paradigm led researchers to move away from this dichotomy and explore the Th1/Th2/Th17 and Treg paradigm in reproductive immunology¹⁰⁹. Th17 cells secrete the cytokines IL-17, IL-21 and IL-22, promoting the inflammatory response during pregnancy in *T. gondii*-infected women¹⁷. Treg cells are key players present in the pregnant uterus, contributing to immune

regulation, decidualization, maternal immune tolerance and acceptance of the fetus^{38,51,53}. Increased Treg cells are positively correlated with the enzyme placental Indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) during pregnancy and are linked to maternal tolerance^{110,111}. IDO expression is induced by IFN γ and converts L-tryptophan, an essential amino acid during pregnancy, into kynurenine, which favours expansion of Treg cells^{111,112}. The importance of these events is evident as reduced levels of kynurenine and other downstream metabolites of tryptophan degradation as well as reduced transcripts for IDO and TDO are associated with fetal growth restriction¹¹¹. Furthermore, IDO expression is increased in the placenta during acute *T. gondii* infection at late gestation¹¹³.

Recently, a decrease in the ratio Treg/Th17 in *T. gondii*-infected pregnant mice was reported, suggesting a role for this imbalance in *T. gondii*-induced embryo loss¹¹⁴. During *T. gondii* infection, a decrease in maternal Treg cells has been reported to disrupt fetal tolerance and to be associated with pregnancy complications¹¹⁵.

9. Progesterone and *T. gondii* infection

Pregnancy-specific factors, such as maternal hormones, are able to modulate the maternal immune response and affect the activation of macrophages and lymphocytes^{41,116,117}. Progesterone (P4), one of the maternal hormones synthesized in the breast, endometrium, brain, ovaries and fetoplacental unit, plays a role during pregnancy by regulating immune cells, essential for the maintenance of pregnancy^{41,42,116,118}. Low levels of P4 in pregnant women infected with *T. gondii* provides another potential adverse effect of *T. gondii* infection on pregnancy¹¹⁹. P4 is able to regulate selectively the expression of different genes associated with alternative macrophage activation⁹². In this study, it has been shown that P4 treatment of murine macrophages selectively reduces transcription of *mrc1* (coding for mannose receptor), but increases transcription of *ym1*, demonstrating plasticity in alternative macrophage activation with potential significant consequences for pregnancy⁹². In addition, P4 contributes to a local Th2-associated cytokines production by murine fetoplacental tissues and recently it has been demonstrated to negatively regulate the differentiation of Th cells into Th1 and Th17^{92,120}. Therefore, it is possible that during *T. gondii* infection, low levels of P4 may be implicated in altered macrophage polarization and T cell responses, negatively affecting pregnancy. Moreover, during pregnancy, progesterone is able to induce the secretion of progesterone-induced blocking factor (PIBF) by progesterone-receptor-positive

lymphocytes¹²¹. PIBF is able to modulate Th1/Th2 balance and contribute to the enhanced Th2 profile noted during pregnancy, characterized by increased production of IL-4 and IL-10¹²¹. Notably, PIBF can also downregulate NK cytotoxicity favoring gestation progression (Figure 1)¹²¹.

10. Conclusion

Successful pregnancy requires a delicate, fine-tuned equilibrium of maternal immune cells at the maternal-fetal interface to promote fetal tolerance. The activation of maternal immune effector cells by infection dysregulate this equilibrium and can lead to fetal loss or fetal infection. There is evidence that *T. gondii* affects the activation states of numerous cells that play pivotal roles at the FMI including dendritic cells, macrophages, NK cells and trophoblasts. Importantly, *T. gondii* disrupts the normal balance of T cell subsets during pregnancy favouring the development of Th1 and Th17 cells associated with parasite control rather than Th2 and Treg cells that are conducive to normal pregnancy. In recent years, scientific advances have contributed to the understanding of the interactions between fetal trophoblasts and maternal immune cells. The effect of *T. gondii* at the maternal-fetal interface is evident in human and murine models, although the mechanisms are not totally clarified. There is still a need for further research into the pregnancy-related mechanisms regulating dDCs, dNK cells, T cells and dM ϕ , upon *T. gondii* infection which might explain adverse pregnancy outcomes and pathological features of congenital toxoplasmosis¹²². Current pre-natal and postnatal treatment can reduce the chance of congenital transmission and the severity of disease sequela, but not prevent either^{4,123}. At present, no vaccine exists to prevent human disease induced by *T. gondii*. The only commercially available vaccine is ToxoVax[®] (Intervet B.V.), which is based on live attenuated tachyzoites of *T. gondii* strain S48, but is only for veterinary use¹²⁴. Greater understanding of the immune response at the local maternal-fetal interface could suggest new targets for therapeutic intervention of congenital toxoplasmosis.

References

1. Carlier Y, Truyens C, Deloron P, Peyron F. Congenital parasitic infections: a review. *Acta tropica*. 2012;121(2):55-70.
2. Wujcicka W, Wilczynski J, Nowakowska D. Do the placental barrier, parasite genotype and Toll-like receptor polymorphisms contribute to the course of primary infection with various *Toxoplasma gondii* genotypes in pregnant women? *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2014;33(5):703-709.
3. Diakoua A, Papadopoulos E, Panousis N, Karatzias C, Giadinis N. *Toxoplasma gondii* and *Neospora caninum* seroprevalence in dairy sheep and goats mixed stock farming. *Veterinary parasitology*. 2013;198(3-4):387-390.
4. Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clinical microbiology reviews*. 2012;25(2):264-296.
5. Su C, Khan A, Zhou P, et al. Globally diverse *Toxoplasma gondii* isolates comprise six major clades originating from a small number of distinct ancestral lineages. *Proc Natl Acad Sci U S A*. 2012;109(15):5844-5849.
6. Lau YL, Lee WC, Gudimella R, et al. Deciphering the Draft Genome of *Toxoplasma gondii* RH Strain. *PloS one*. 2016;11(6):e0157901.
7. Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and *Toxoplasma gondii* during acute and chronic infection. *BMC genomics*. 2014;15:806.
8. Halonen SK, Weiss LM. Toxoplasmosis. *Handbook of clinical neurology*. 2013;114:125-145.
9. Severance EG, Xiao J, Jones-Brando L, et al. *Toxoplasma gondii*-A Gastrointestinal Pathogen Associated with Human Brain Diseases. *International review of neurobiology*. 2016;131:143-163.
10. Hunter CA, Sibley LD. Modulation of innate immunity by *Toxoplasma gondii* virulence effectors. *Nat Rev Microbiol*. 2012;10(11):766-778.
11. Chaudhry SA, Gad N, Koren G. Toxoplasmosis and pregnancy. *Canadian family physician Medecin de famille canadien*. 2014;60(4):334-336.
12. McAuley JB. Congenital Toxoplasmosis. *Journal of the Pediatric Infectious Diseases Society*. 2014;3 Suppl 1:S30-35.
13. Vitaliano SN, Soares HS, Minervino AH, et al. Genetic characterization of *Toxoplasma gondii* from Brazilian wildlife revealed abundant new genotypes. *International journal for parasitology Parasites and wildlife*. 2014;3(3):276-283.
14. Meerburg BG, De Craeye S, Dierick K, Kijlstra A. *Neospora caninum* and *Toxoplasma gondii* in brain tissue of feral rodents and insectivores caught on farms in the Netherlands. *Veterinary parasitology*. 2012;184(2-4):317-320.
15. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. *Semin Immunopathol*. 2012;34(6):793-813.
16. Menzies FM, Macphail D, Henriquez FL. The role of chemokines and their receptors during protist parasite infections. *Parasitology*. 2016;143(14):1890-1901.
17. Silva JL, Rezende-Oliveira K, da Silva MV, et al. IL-17-expressing CD4(+) and CD8(+) T lymphocytes in human toxoplasmosis. *Mediators Inflamm*. 2014;2014:573825.
18. Ibrahim HM, Nishimura M, Tanaka S, et al. Overproduction of *Toxoplasma gondii* cyclophilin-18 regulates host cell migration and enhances parasite dissemination in a CCR5-independent manner. *BMC Microbiol*. 2014;14:76.
19. Pittman KJ, Knoll LJ. Long-Term Relationships: the Complicated Interplay between the Host and the Developmental Stages of *Toxoplasma gondii* during Acute and Chronic Infections. *Microbiology and molecular biology reviews : MMBR*. 2015;79(4):387-401.
20. Sturge CR, Yarovinsky F. Complex immune cell interplay in the gamma interferon response during *Toxoplasma gondii* infection. *Infection and immunity*. 2014;82(8):3090-3097.

21. Gazzinelli RT, Wysocka M, Hieny S, et al. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. *Journal of immunology (Baltimore, Md : 1950)*. 1996;157(2):798-805.
22. Thouvenin M, Candolfi E, Villard O, Klein JP, Kien T. Immune response in a murine model of congenital toxoplasmosis: increased susceptibility of pregnant mice and transplacental passage of *Toxoplasma gondii* are type 2-dependent. *Parassitologia*. 1997;39(4):279-283.
23. Li XL, Wei HX, Zhang H, Peng HJ, Lindsay DS. A meta analysis on risks of adverse pregnancy outcomes in *Toxoplasma gondii* infection. *PLoS one*. 2014;9(5):e97775.
24. Kieffer F, Wallon M. Congenital toxoplasmosis. *Handbook of clinical neurology*. 2013;112:1099-1101.
25. Opsteegh M, Kortbeek TM, Havelaar AH, van der Giessen JW. Intervention strategies to reduce human *Toxoplasma gondii* disease burden. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2015;60(1):101-107.
26. Hennequin C, Dureau P, N'Guyen L, Thulliez P, Gagelin B, Dufier JL. CONGENITAL TOXOPLASMOSIS ACQUIRED FROM AN IMMUNE WOMAN. *The Pediatric Infectious Disease Journal*. 1997;16(1):75-77.
27. Garweg JG, Scherrer J, Wallon M, Kodjikian L, Peyron F. Reactivation of ocular toxoplasmosis during pregnancy. *BJOG : an international journal of obstetrics and gynaecology*. 2005;112(2):241-242.
28. Campos FA, Andrade GM, Lanna Ade P, Lage BF, Assumpcao MV, Pinto JA. Incidence of congenital toxoplasmosis among infants born to HIV-coinfected mothers: case series and literature review. *Braz J Infect Dis*. 2014;18(6):609-617.
29. Calamy L, Goudjil F, Godineau N, Bolot P. [Severe congenital toxoplasmosis secondary to toxoplasma reactivation in an HIV-infected mother]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 2015;22(2):181-184.
30. Braakenburg AM, Crespi CM, Holland GN, Wu S, Yu F, Rothova A. Recurrence rates of ocular toxoplasmosis during pregnancy. *Am J Ophthalmol*. 2014;157(4):767-773 e762.
31. Xiao J, Yolken RH. Strain hypothesis of *Toxoplasma gondii* infection on the outcome of human diseases. *Acta physiologica (Oxford, England)*. 2015;213(4):828-845.
32. Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. Understanding the complexity of the immune system during pregnancy. *American journal of reproductive immunology (New York, NY : 1989)*. 2014;72(2):107-116.
33. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. *Nature reviews Immunology*. 2017;17(8):469-482.
34. Sharkey DJ, Tremellen KP, Briggs NE, Dekker GA, Robertson SA. Seminal plasma pro-inflammatory cytokines interferon-gamma (IFNG) and C-X-C motif chemokine ligand 8 (CXCL8) fluctuate over time within men. *Human reproduction (Oxford, England)*. 2017;32(7):1373-1381.
35. Adefuye AO, Adeola HA, Sales KJ, Katz AA. Seminal Fluid-Mediated Inflammation in Physiology and Pathology of the Female Reproductive Tract. *Journal of immunology research*. 2016;2016:9707252.
36. Robertson SA, Moldenhauer LM. Immunological determinants of implantation success. *The International journal of developmental biology*. 2014;58(2-4):205-217.
37. Svensson-Arelund J, Ernerudh J. The Role of Macrophages in Promoting and Maintaining Homeostasis at the Fetal-Maternal Interface. *American journal of reproductive immunology (New York, NY : 1989)*. 2015;74(2):100-109.
38. Lee SK, Kim CJ, Kim DJ, Kang JH. Immune cells in the female reproductive tract. *Immune network*. 2015;15(1):16-26.

39. Abrahams VM, Kim YM, Straszewski SL, Romero R, Mor G. Macrophages and apoptotic cell clearance during pregnancy. *American journal of reproductive immunology (New York, NY : 1989)*. 2004;51(4):275-282.
40. Zhang L, Zhao M, Jiao F, et al. Interferon gamma is involved in apoptosis of trophoblast cells at the maternal-fetal interface following *Toxoplasma gondii* infection. *Int J Infect Dis*. 2015;30:10-16.
41. Schumacher A, Costa SD, Zenclussen AC. Endocrine factors modulating immune responses in pregnancy. *Frontiers in immunology*. 2014;5:196.
42. Halasz M, Szekeres-Bartho J. The role of progesterone in implantation and trophoblast invasion. *Journal of reproductive immunology*. 2013;97(1):43-50.
43. Suman P, Malhotra SS, Gupta SK. LIF-STAT signaling and trophoblast biology. *Jak-stat*. 2013;2(4):e25155.
44. Fraccaroli L, Alfieri J, Larocca L, et al. A potential tolerogenic immune mechanism in a trophoblast cell line through the activation of chemokine-induced T cell death and regulatory T cell modulation. *Human reproduction (Oxford, England)*. 2009;24(1):166-175.
45. Tabiasco J, Rabot M, Aguerre-Girr M, et al. Human decidual NK cells: unique phenotype and functional properties -- a review. *Placenta*. 2006;27 Suppl A:S34-39.
46. Teles A, Zenclussen AC, Schumacher A. Regulatory T cells are baby's best friends. *American journal of reproductive immunology (New York, NY : 1989)*. 2013;69(4):331-339.
47. Nourollahpour Shiadeh M, Niyiyati M, Fallahi S, Rostami A. Human parasitic protozoan infection to infertility: a systematic review. *Parasitology Research*. 2016;115(2):469-477.
48. Liu X, Zhao M, Yang X, et al. *Toxoplasma gondii* infection of decidual CD1c(+) dendritic cells enhances cytotoxicity of decidual natural killer cells. *Inflammation*. 2014;37(4):1261-1270.
49. Kankova S, Prochazkova L, Flegr J, Calda P, Springer D, Potlukova E. Effects of latent toxoplasmosis on autoimmune thyroid diseases in pregnancy. *PLoS One*. 2014;9(10):e110878.
50. Tosh KW, Mittereder L, Bonne-Annee S, et al. The IL-12 Response of Primary Human Dendritic Cells and Monocytes to *Toxoplasma gondii* Is Stimulated by Phagocytosis of Live Parasites Rather Than Host Cell Invasion. *J Immunol*. 2016;196(1):345-356.
51. Svensson-Arvelund J, Mehta RB, Lindau R, et al. The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages. *Journal of immunology (Baltimore, Md : 1950)*. 2015;194(4):1534-1544.
52. Kostlin N, Kugel H, Spring B, et al. Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. *European journal of immunology*. 2014;44(9):2582-2591.
53. Ghaebi M, Nouri M, Ghasemzadeh A, et al. Immune regulatory network in successful pregnancy and reproductive failures. *Biomed Pharmacother*. 2017;88:61-73.
54. Robbins JR, Zeldovich VB, Poukchanski A, Boothroyd JC, Bakardjiev AI. Tissue barriers of the human placenta to infection with *Toxoplasma gondii*. *Infection and immunity*. 2012;80(1):418-428.
55. Angeloni MB, Girelli PM, Franco PS, et al. Differential apoptosis in BeWo cells after infection with highly (RH) or moderately (ME49) virulent strains of *Toxoplasma gondii* is related to the cytokine profile secreted, the death receptor Fas expression and phosphorylated ERK1/2 expression. *Placenta*. 2013;34(11):973-982.
56. Rezende-Oliveira K, Silva NM, Mineo JR, Rodrigues Junior V. Cytokines and chemokines production by mononuclear cells from parturient women after stimulation with live *Toxoplasma gondii*. *Placenta*. 2012;33(9):682-687.
57. Fonseca BM, Correia-da-Silva G, Teixeira NA. The rat as an animal model for fetoplacental development: a reappraisal of the post-implantation period. *Reproductive biology*. 2012;12(2):97-118.

58. Du MR, Wang SC, Li DJ. The integrative roles of chemokines at the maternal-fetal interface in early pregnancy. *Cellular & molecular immunology*. 2014;11(5):438-448.
59. Abrahams VM, Mor G. Toll-like receptors and their role in the trophoblast. *Placenta*. 2005;26(7):540-547.
60. Liempi A, Castillo C, Carrillo I, et al. A local innate immune response against *Trypanosoma cruzi* in the human placenta: The epithelial turnover of the trophoblast. *Microbial pathogenesis*. 2016;99:123-129.
61. Abrahams VM, Straszewski-Chavez SL, Guller S, Mor G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. *Molecular human reproduction*. 2004;10(1):55-63.
62. Koga K, Cardenas I, Aldo P, et al. Activation of TLR3 in the trophoblast is associated with preterm delivery. *American journal of reproductive immunology (New York, NY : 1989)*. 2009;61(3):196-212.
63. Krishnan L, Nguyen T, McComb S. From mice to women: the conundrum of immunity to infection during pregnancy. *Journal of reproductive immunology*. 2013;97(1):62-73.
64. Di Simone N, Di Nicuolo F, Marana R, et al. Synthetic PreImplantation Factor (PIF) prevents fetal loss by modulating LPS induced inflammatory response. *PloS one*. 2017;12(7):e0180642.
65. Barbosa BF, Paulesu L, Ietta F, et al. Susceptibility to *Toxoplasma gondii* proliferation in BeWo human trophoblast cells is dose-dependent of macrophage migration inhibitory factor (MIF), via ERK1/2 phosphorylation and prostaglandin E2 production. *Placenta*. 2014;35(3):152-162.
66. Barbosa BF, Lopes-Maria JB, Gomes AO, et al. IL10, TGF beta1, and IFN gamma modulate intracellular signaling pathways and cytokine production to control *Toxoplasma gondii* infection in BeWo trophoblast cells. *Biology of reproduction*. 2015;92(3):82.
67. Ander SE, Rudzki EN, Arora N, Sadovsky Y, Coyne CB, Boyle JP. Human Placental Syncytiotrophoblasts Restrict *Toxoplasma gondii* Attachment and Replication and Respond to Infection by Producing Immunomodulatory Chemokines. *mBio*. 2018;9(1).
68. Freier CP, Kuhn C, Rapp M, et al. Expression of CCL22 and Infiltration by Regulatory T Cells are Increased in the Decidua of Human Miscarriage Placentas. *American journal of reproductive immunology (New York, NY : 1989)*. 2015;74(3):216-227.
69. Zhao M, Zhang R, Xu X, et al. IL-10 reduces levels of apoptosis in *Toxoplasma gondii*-infected trophoblasts. *PLoS One*. 2013;8(2):e56455.
70. Castro AS, Alves CM, Angeloni MB, et al. Trophoblast cells are able to regulate monocyte activity to control *Toxoplasma gondii* infection. *Placenta*. 2013;34(3):240-247.
71. Guirelli PM, Angeloni MB, Barbosa BF, et al. Trophoblast-macrophage crosstalk on human extravillous under *Toxoplasma gondii* infection. *Placenta*. 2015;36(10):1106-1114.
72. Vacca P, Montaldo E, Vitale C, Croxatto D, Moretta L, Mingari MC. MSC and innate immune cell interactions: A lesson from human decidua. *Immunology letters*. 2015;168(2):170-174.
73. Xu X, Wang Q, Deng B, et al. Monocyte chemoattractant protein-1 secreted by decidual stromal cells inhibits NK cells cytotoxicity by up-regulating expression of SOCS3. *PloS one*. 2012;7(7):e41869.
74. Wang S, Cao C, Piao H, et al. Tim-3 protects decidual stromal cells from toll-like receptor-mediated apoptosis and inflammatory reactions and promotes Th2 bias at the maternal-fetal interface. *Scientific reports*. 2015;5:9013.
75. Mori M, Bogdan A, Balassa T, Csabai T, Szekeres-Bartho J. The decidua-the maternal bed embracing the embryo-maintains the pregnancy. *Seminars in immunopathology*. 2016;38(6):635-649.
76. Faas MM, de Vos P. Uterine NK cells and macrophages in pregnancy. *Placenta*. 2017;56:44-52.

77. Nishimura M, Umeda K, Suwa M, Furuoka H, Nishikawa Y. CCR5 Is Involved in Interruption of Pregnancy in Mice Infected with *Toxoplasma gondii* during Early Pregnancy. *Infection and immunity*. 2017;85(9).
78. Zhang D, Sun X, Ren L, et al. Proteomic profiling of human decidual immune proteins during *Toxoplasma gondii* infection. *Journal of proteomics*. 2018.
79. Lee CH, Kim TH, Lee JH, et al. Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway Is Required for Endometrial Decidualization in Mice and Human. *PLoS one*. 2013;8(9):e75282.
80. Sahin E, Haubenwallner S, Kuttke M, et al. Macrophage PTEN Regulates Expression and Secretion of Arginase I Modulating Innate and Adaptive Immune Responses. *The Journal of Immunology*. 2014;193(4):1717-1727.
81. Jabrane-Ferrat N, Siewiera J. The up side of decidual natural killer cells: new developments in immunology of pregnancy. *Immunology*. 2014;141(4):490-497.
82. Ratsep MT, Felker AM, Kay VR, Tolusso L, Hofmann AP, Croy BA. Uterine natural killer cells: supervisors of vasculature construction in early decidua basalis. *Reproduction (Cambridge, England)*. 2015;149(2):R91-102.
83. Xu X, Zhao M, Liu X, et al. *Toxoplasma gondii* infection regulates the balance of activating and inhibitory receptors on decidual natural killer cells. *PLoS one*. 2013;8(2):e55432.
84. Guenther S, Vrekoussis T, Heublein S, et al. Decidual macrophages are significantly increased in spontaneous miscarriages and over-express FasL: a potential role for macrophages in trophoblast apoptosis. *International journal of molecular sciences*. 2012;13(7):9069-9080.
85. Zhang YH, He M, Wang Y, Liao AH. Modulators of the Balance between M1 and M2 Macrophages during Pregnancy. *Front Immunol*. 2017;8:120.
86. Dallagi A, Girouard J, Hamelin-Morrisette J, et al. The activating effect of IFN-gamma on monocytes/macrophages is regulated by the LIF-trophoblast-IL-10 axis via Stat1 inhibition and Stat3 activation. *Cellular & molecular immunology*. 2015;12(3):326-341.
87. Brown MB, von Chamier M, Allam AB, Reyes L. M1/M2 macrophage polarity in normal and complicated pregnancy. *Frontiers in immunology*. 2014;5:606.
88. Chabtni L, Mfarrej B, Mounayar M, et al. TIM-3 regulates innate immune cells to induce fetomaternal tolerance. *Journal of immunology (Baltimore, Md : 1950)*. 2013;190(1):88-96.
89. Patil V, Zhao Y, Shah S, et al. Co-existence of classical and alternative activation programs in macrophages responding to *Toxoplasma gondii*. *International journal for parasitology*. 2014;44(2):161-164.
90. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. *Nature*. 2013;496(7446):445-455.
91. Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. *Immunity*. 2016;44(3):450-462.
92. Menzies FM, Henriquez FL, Alexander J, Roberts CW. Selective inhibition and augmentation of alternative macrophage activation by progesterone. *Immunology*. 2011;134(3):281-291.
93. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nature reviews Immunology*. 2011;11(11):723-737.
94. Mills CD, Lenz LL, Ley K. Macrophages at the fork in the road to health or disease. *Frontiers in immunology*. 2015;6:59.
95. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. *The Journal of pathology*. 2013;229(2):176-185.
96. Porta C, Riboldi E, Ippolito A, Sica A. Molecular and epigenetic basis of macrophage polarized activation. *Seminars in immunology*. 2015;27(4):237-248.
97. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity*. 2014;41(1):14-20.
98. Fox BA, Gigley JP, Bzik DJ. *Toxoplasma gondii* lacks the enzymes required for de novo arginine biosynthesis and arginine starvation triggers cyst formation. *International journal for parasitology*. 2004;34(3):323-331.

99. Kong L, Zhang Q, Chao J, et al. Polarization of macrophages induced by *Toxoplasma gondii* and its impact on abnormal pregnancy in rats. *Acta tropica*. 2015;143:1-7.
100. Li Z, Zhao M, Li T, et al. Decidual Macrophage Functional Polarization during Abnormal Pregnancy due to *Toxoplasma gondii*: Role for LILRB4. *Frontiers in immunology*. 2017;8:1013.
101. Manirakiza A, Serdouma E, Ngbale RN, et al. A brief review on features of falciparum malaria during pregnancy. *Journal of public health in Africa*. 2017;8(2):668.
102. Souza RM, Ataide R, Dombrowski JG, et al. Placental histopathological changes associated with *Plasmodium vivax* infection during pregnancy. *PLoS neglected tropical diseases*. 2013;7(2):e2071.
103. Erlebacher A. Immunology of the maternal-fetal interface. *Annual review of immunology*. 2013;31:387-411.
104. Bartmann C, Segerer SE, Rieger L, Kapp M, Sutterlin M, Kammerer U. Quantification of the predominant immune cell populations in decidua throughout human pregnancy. *American journal of reproductive immunology (New York, NY : 1989)*. 2014;71(2):109-119.
105. Tirado-Gonzalez I, Munoz-Fernandez R, Prados A, et al. Apoptotic DC-SIGN+ cells in normal human decidua. *Placenta*. 2012;33(4):257-263.
106. Leno-Duran E, Munoz-Fernandez R, Olivares EG, Tirado-Gonzalez I. Liaison between natural killer cells and dendritic cells in human gestation. *Cellular & molecular immunology*. 2014;11(5):449-455.
107. Gorvel L, Ben Amara A, Ka MB, Textoris J, Gorvel JP, Mege JL. Myeloid decidual dendritic cells and immunoregulation of pregnancy: defective responsiveness to *Coxiella burnetii* and *Brucella abortus*. *Frontiers in cellular and infection microbiology*. 2014;4:179.
108. Wang WJ, Hao CF, Lin QD. Dysregulation of macrophage activation by decidual regulatory T cells in unexplained recurrent miscarriage patients. *Journal of reproductive immunology*. 2011;92(1-2):97-102.
109. Figueiredo AS, Schumacher A. The T helper type 17/regulatory T cell paradigm in pregnancy. *Immunology*. 2016;148(1):13-21.
110. Yu LL, Zhang YH, Zhao FX. Expression of indoleamine 2,3-dioxygenase in pregnant mice correlates with CD4+CD25+Foxp3+ T regulatory cells. *European review for medical and pharmacological sciences*. 2017;21(8):1722-1728.
111. Murthi P, Wallace EM, Walker DW. Altered placental tryptophan metabolic pathway in human fetal growth restriction. *Placenta*. 2017;52:62-70.
112. Badawy AA. Tryptophan metabolism, disposition and utilization in pregnancy. *Bioscience reports*. 2015;35(5).
113. Pfaff AW, Mousli M, Senegas A, et al. Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following *Toxoplasma gondii* infection. *International journal for parasitology*. 2008;38(2):249-258.
114. Zhang H, Hu X, Liu X, Zhang R, Fu Q, Xu X. The Treg/Th17 imbalance in *Toxoplasma gondii*-infected pregnant mice. *American journal of reproductive immunology (New York, NY : 1989)*. 2012;67(2):112-121.
115. Rowe JH, Ertelt JM, Xin L, Way SS. Regulatory T cells and the immune pathogenesis of prenatal infection. *Reproduction (Cambridge, England)*. 2013;146(6):R191-203.
116. Wolfson ML, Schander JA, Bariani MV, Correa F, Franchi AM. Progesterone modulates the LPS-induced nitric oxide production by a progesterone-receptor independent mechanism. *European journal of pharmacology*. 2015;769:110-116.
117. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. *Hormones and behavior*. 2012;62(3):263-271.
118. Lissauer D, Eldershaw SA, Inman CF, Coomarasamy A, Moss PA, Kilby MD. Progesterone promotes maternal-fetal tolerance by reducing human maternal T-cell polyfunctionality and


inducing a specific cytokine profile. *European journal of immunology*. 2015;45(10):2858-2872.

119. Galvan-Ramirez Mde L, Gutierrez-Maldonado AF, Verduzco-Grijalva F, Jimenez JM. The role of hormones on *Toxoplasma gondii* infection: a systematic review. *Frontiers in microbiology*. 2014;5:503.
120. Maeda Y, Ohtsuka H, Tomioka M, Oikawa M. Effect of progesterone on Th1/Th2/Th17 and regulatory T cell-related genes in peripheral blood mononuclear cells during pregnancy in cows. *Veterinary research communications*. 2013;37(1):43-49.
121. Szekeres-Bartho J. The Role of Progesterone in the Feto-Maternal Immunological Crosstalk. *Medical principles and practice : international journal of the Kuwait University, Health Science Centre*. 2018.
122. PrabhuDas M, Bonney E, Caron K, et al. Immune mechanisms at the maternal-fetal interface: perspectives and challenges. *Nature immunology*. 2015;16(4):328-334.
123. McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? *Memorias do Instituto Oswaldo Cruz*. 2009;104(2):320-344.
124. Fereig RM, Kuroda Y, Terkawi MA, Mahmoud ME, Nishikawa Y. Immunization with *Toxoplasma gondii* peroxiredoxin 1 induces protective immunity against toxoplasmosis in mice. *PloS one*. 2017;12(4):e0176324.

Figure Legends

Figure 1. **The immune response developing to acute *Toxoplasma gondii* infection (green) and the immune response changes during pregnancy are mutually antagonistic (red).** Physiological changes are in grey. (A) *T. gondii* have a number of pathogen-associated molecular patterns (PAMPs; including HSP70, GIPLS and profilin) which can ligate TLRs on host cells and a chemokine mimic, cyclophilin18, that binds CCR5 to induce activation of neutrophils, dendritic cells and macrophages. (B) IL-12 produced by these cells act on NK cells to stimulate them to produce IFN- γ . (C) Together, IFN- γ and IL-12 preferentially induce differentiation of Th1 cells. (D) Th1 cells secrete IFN- γ and, preferentially favour M1 macrophage activation. (E) Th2 cells and Treg cells play a role in reducing inflammation during *T. gondii* infection. (F) Pregnancy is associated with an increase in progesterone production that stimulates NK cells and T cells to produce PIBF, which downregulates NK cell activity and promotes Th2 expansion. (G) Interaction of NK cells with atypical HLAs (HLA-C, E and G) in the maternal-fetal interface inhibits NK cell activation. (H) indolamine deoxygenase (IDO) induced in monocytes results in degradation of tryptophan and the production of kynurenine which in turn expands Treg cells. (I) Th2 cells produce IL-4 and IL-13 which favours M2 macrophage activation. (J) Progesterone levels are known to be downregulated during *T. gondii* infection although it is not known if this is via direct effects or indirectly through inflammation. The exact interaction of pregnancy and the developing immune response to *T. gondii* infection will be dependent on when during pregnancy infection occurs.

Figure 2: Impact of *T. gondii* infection in pregnancy. Clinical consequences for the fetus and newborn and concomitant alteration to maternal immune mediators at the FMI and hormonal alterations (Blue: relative levels during normal pregnancy; Red arrows: effect of *T. gondii* infection on these levels during pregnancy and infection). nd: not described.



Trimester of Maternal Acquisition	I	II	III
Incidence of Transmission	17%	25%	65%
Relative Severity of Congenital Disease	Severe	Intermediate	Mild or Asymptomatic
Consequences for fetus and disease manifestations in newborn Clinical manifestations	 High risk of abortion, stillbirth or premature birth	 Intermediate risk of abortion, still birth, premature birth, blindness, chorioretinitis, mental retardation, neurological alterations or death	 High risk of congenital infection. Low risk of overt clinical manifestations in newborn
CCL22	↑	↑	↑
IL-12, IFN-γ	↑	↑	↑
IL-1β	↑↑	nd	nd
Granzyme A, C/EBPβ	↑	nd	nd
NKG2D	↑	nd	nd
Th2 & Treg CD4 T cells	↓	↓↓	↓↓↓
Macrophage Activation	M1+ ↑, M2+ ↓	M1+ ↑, M2++ ↓	M1+ ↑, M2++ ↓
Tryptophan degradation	↑	↑	↑
Progesterone	↓	↓	↓
Estrogen	↓	↓	↓